Affordable Access

deepdyve-link
Publisher Website

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action

Authors
  • Assadi, Majid1
  • Rekabpour, Seyed Javad2
  • Amini, Abdullatif3
  • Dadgar, Habibollah4
  • Nemati, Reza5
  • Gholamrezanezhad, Ali6
  • Nabipour, Iraj7
  • Jafari, Esmail1
  • Ahmadzadehfar, Hojjat8
  • 1 Bushehr University of Medical Sciences, Bushehr Medical University Hospital, The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy, Bushehr, Iran
  • 2 Bushehr University of Medical Sciences, Bushehr Medical University Hospital, Department of Oncology, Bushehr, Iran
  • 3 Bushehr University of Medical Sciences, Bushehr Medical Heart Center, Department of Cardiology, Bushehr, Iran
  • 4 Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran
  • 5 Bushehr University of Medical Sciences, Bushehr Medical University Hospital, Department of Neurology, Bushehr, Iran
  • 6 University of Southern California, Keck School of Medicine, Department of Radiology, Los Angeles, USA
  • 7 Bushehr University of Medical Sciences, Bushehr Medical University Hospital, Department of Internal Medicine, Division of Endocrinology, Bushehr, Iran
  • 8 Klinikum Westfalen, Department of Nuclear Medicine, Dortmund, Germany
Type
Published Article
Journal
Molecular Imaging and Radionuclide Therapy
Publisher
Galenos Publishing
Publication Date
Jun 03, 2021
Volume
30
Issue
2
Pages
107–109
Identifiers
DOI: 10.4274/mirt.galenos.2020.69783
PMID: 34082512
PMCID: PMC8185482
Source
PubMed Central
Keywords
Disciplines
  • Interesting Image
License
Unknown

Abstract

We present a partial response of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In addition to the valuable role of PRRT in inoperable NETs, it has been demonstrated that this treatment can be a promising therapy for progressive meningioma, especially in patients with low grade and refractory to standard regime.

Report this publication

Statistics

Seen <100 times